Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spevatamig + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Phanes Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Spevatamig (PT886) + FOLFIRINOX is a combination cancer therapy that combines **spevatamig** (a monoclonal antibody drug under investigation, code name PT886) with the **FOLFIRINOX chemotherapy regimen** (folinic acid/leucovorin, fluorouracil, irinotecan, and oxaliplatin)[3][5]. Spevatamig targets the Claudin 18.2 protein, aiming to enhance anti-tumor activity. FOLFIRINOX is a well-established first-line chemotherapy regimen for advanced pancreatic cancer, utilizing multiple agents to disrupt DNA synthesis and repair, inhibit topoisomerase I, and enhance fluorouracil activity[2][4][6]. The combination is being evaluated for metastatic or locally advanced pancreatic ductal adenocarcinoma (PDAC)[3][5].
- Other names
- PT886PT-886PT 886FOLFIRINOXspevatamig + FOLFIRINOX
02
Targets
CD47 (Cluster of Differentiation 47)Claudin 18.2TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on spevatamig + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spevatamig + FOLFIRINOX.